Javascript must be enabled to continue!
Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis
View through CrossRef
AbstractBackground and Aims: Primary biliary cirrhosis (PBC) has been reported in up to 4–6% of first degree relatives of patients with the disease. In addition, immune abnormalities, including hypergammaglobulinemia, autoantibodies and increased frequency of autoimmune disorders, were reported in family members of PBC patients. The aim of the present study was to investigate the prevalence of PBC in relatives of patients with PBC, and to investigate the occurrence of chronic liver disease (CLD) and immune abnormalities in these subjects.Methods: One‐hundred first degree relatives of 26 patients with PBC were interviewed and submitted to physical examination and determination of liver enzymes, γ‐globulin, bilirubin and auto‐antibodies, including antinuclear (ANA), antismooth muscle (SMA), antimitochondrial antibodies (AMA) by indirect immunofluorescence (IIF) and anti‐M2 antibody by immunoblotting (IB).Results: Immune disturbances were rarely observed in relatives of PBC patients. Higher γ‐globulin levels, SMA and ANA were detected in four, eight and two family members, respectively. In most subjects, these autoantibodies were either in low titers or associated with concurrent diseases. Only four relatives had extrahepatic autoimmune diseases and another eight exhibited other CLD. Primary biliary cirrhosis was detected in a sister of one patient. Additionally, two other relatives of PBC patients who tested negative for AMA by IIF showed reactivity for anti‐M2 by IB.Conclusions: Immune disturbances, including ANA and SMA, are uncommon in family members of PBC patients. Conversely, anti‐M2 antibodies and overt PBC do occur in relatives of PBC patients, even in Brazil where the disease is quite rare.
Title: Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis
Description:
AbstractBackground and Aims: Primary biliary cirrhosis (PBC) has been reported in up to 4–6% of first degree relatives of patients with the disease.
In addition, immune abnormalities, including hypergammaglobulinemia, autoantibodies and increased frequency of autoimmune disorders, were reported in family members of PBC patients.
The aim of the present study was to investigate the prevalence of PBC in relatives of patients with PBC, and to investigate the occurrence of chronic liver disease (CLD) and immune abnormalities in these subjects.
Methods: One‐hundred first degree relatives of 26 patients with PBC were interviewed and submitted to physical examination and determination of liver enzymes, γ‐globulin, bilirubin and auto‐antibodies, including antinuclear (ANA), antismooth muscle (SMA), antimitochondrial antibodies (AMA) by indirect immunofluorescence (IIF) and anti‐M2 antibody by immunoblotting (IB).
Results: Immune disturbances were rarely observed in relatives of PBC patients.
Higher γ‐globulin levels, SMA and ANA were detected in four, eight and two family members, respectively.
In most subjects, these autoantibodies were either in low titers or associated with concurrent diseases.
Only four relatives had extrahepatic autoimmune diseases and another eight exhibited other CLD.
Primary biliary cirrhosis was detected in a sister of one patient.
Additionally, two other relatives of PBC patients who tested negative for AMA by IIF showed reactivity for anti‐M2 by IB.
Conclusions: Immune disturbances, including ANA and SMA, are uncommon in family members of PBC patients.
Conversely, anti‐M2 antibodies and overt PBC do occur in relatives of PBC patients, even in Brazil where the disease is quite rare.
Related Results
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Abstract
Funding Acknowledgements
Type of funding sources: None.
INTRODUCTION Patients with heart failure (HF)...
Primary PCI: a reasonable treatment for STEMI care during the COVID-19 pandemic
Primary PCI: a reasonable treatment for STEMI care during the COVID-19 pandemic
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
...
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
<p><em><span style="font-size: 11.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-langua...
On Flores Island, do "ape-men" still exist? https://www.sapiens.org/biology/flores-island-ape-men/
On Flores Island, do "ape-men" still exist? https://www.sapiens.org/biology/flores-island-ape-men/
<span style="font-size:11pt"><span style="background:#f9f9f4"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><spa...
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

